tbuckley/cabot-search huggingface dataset:
Relationships Between Income, Health Behaviors, and Life Expectancy—Reply
Authors: Raj Chetty, Michael Stepner, David Cutler
Journal: JAMA (2016)

In Reply Dr Fiscella notes that there was a negative correlation between discharges for ambulatory care–sensitive conditions and life expectancy at the county level, as reported in the supplemental appendix in our study. Fiscella correctly notes that this finding is worthy of further investigation.
Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia
Authors: Patrick D. Bhola, Brenton G. Mar, R. Coleman Lindsley, Jeremy A. Ryan, Leah J. Hogdal, Thanh Trang Vo, Daniel J. DeAngelo, Ilene Galinsky, Benjamin L. Ebert, Anthony Letai
Journal: Journal of Clinical Investigation (2016)

Upfront resistance to chemotherapy and relapse following remission are critical problems in leukemia that are generally attributed to subpopulations of chemoresistant tumor cells. There are, however, limited means for prospectively identifying these subpopulations, which hinders an understanding of therapeutic resistance. BH3 profiling is a functional single-cell analysis using synthetic BCL-2 BH3 domain-like peptides that measures mitochondrial apoptotic sensitivity or "priming." Here, we observed that the extent of apoptotic priming is heterogeneous within multiple cancer cell lines and is not the result of experimental noise. Apoptotic priming was also heterogeneous in treatment-naive primary human acute myeloid leukemia (AML) myeloblasts, and this heterogeneity decreased in chemotherapy-treated AML patients. The priming of the most apoptosis-resistant tumor cells, rather than the median priming of the population, best predicted patient response to induction chemotherapy. For several patients, these poorly primed subpopulations of AML tumor cells were enriched for antiapoptotic proteins. Developing techniques to identify and understand these apoptosis-insensitive subpopulations of tumor cells may yield insights into clinical chemoresistance and potentially improve therapeutic outcomes in AML.
JAK2V617F Mutation Screening as Part of the Hypercoagulable Workup in the Absence of Splanchnic Vein Thrombosis: Assessment of Value in a Series of 664 Consecutive Patients.
Authors: Animesh Pardanani, Terra L. Lasho, Kebede Hussein, Susan Schwager, Christy Finke, Rajiv K. Pruthi, Ayalew Tefferi
Journal: Blood (2007)
Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension
Authors: Peter J. Hutchinson, Angelos G. Kolias, Ivan S. Timofeev, Elizabeth A. Corteen, Marek Czosnyka, Jake Timothy, Ian Anderson, Diederik O. Bulters, Antonio Belli, C. Andrew Eynon, John Wadley, A. David Mendelow, Patrick M. Mitchell, Mark H. Wilson, Giles Critchley, Juan Sahuquillo, Andreas Unterberg, Franco Servadei, Graham M. Teasdale, John D. Pickard, David K. Menon, Gordon D. Murray, Peter J. Kirkpatrick
Journal: New England Journal of Medicine (2016)

The effect of decompressive craniectomy on clinical outcomes in patients with refractory traumatic intracranial hypertension remains unclear.
An incidence of renal failure in patients receiving renally adjusted zoledronic acid.
Authors: S. Shah, G. W. Jean, S. V. Keisner, S. M. GressettUssery, J. Dowell
Journal: Journal of Clinical Oncology (2010)

e19581 Background: Acute renal failure (ARF) is an adverse event associated with the use of zoledronic acid, which was recognized during the registry trial. In 2005, the FDA label recommended specific zoledronic acid dosing based on creatinine clearance in renally impaired cancer patients. There is a lack of literature regarding the clinical impact of this recommendation. Methods: This was a retrospective, single institution study evaluating all patients receiving zoledronic acid from August 29, 2001 to September 30, 2009. Patients were eligible if they had cancer with bone metastasis and received at least 1 infusion of zoledronic acid. Any patients receiving zoledronic acid within 14 days of previous dose or having ARF within 1 month of eligibility were excluded. Acute renal failure was defined as an increase in serum creatinine (SCr) of 0.5 or 1.0 for baseline SCr was <1.4 or ≥ 1.4, respectively. Results: 220 patients met the study inclusion criteria, 184 with normal baseline renal function (Creatinine Clearance (CrCl) of > 60 mL/min; group 1 (G1)) and 36 with impaired renal function (CrCl 30 to 60 mL/min; group 2 (G2)). Prostate cancer (G1 49% vs. G2 64%) and multiple myeloma (G1 20% vs. G2 19%) were the most common cancers between the groups. There was a significant difference in mean age (G1 64 vs. G2 75 years; p<0.05) and CrCL (G1 91 vs. G2 49 mL/min; p<0.05) at baseline. There were 38 patients (20.7%) who developed renal failure in G1compared with 7 patients (19.4%) in G2 (p = 0.87). The mean time to ARF was 6.1 months in both groups (p = NS). Acute renal failure based on CrCL (≥ 25% decline in CrCL) was similar between groups (G1 39.1% vs. G2 41.7; p = 0.78), as well. One patient in each group required dialysis due to renal failure. Conclusions: The incidence of acute renal failure is similar between patients with normal baseline renal function compared with impaired function when zoledronic acid dose is appropriately adjusted in renally impaired patients. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis
An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)
Authors: Andrea Kuendgen, Heinz Tuechler, Meritxell Nomdedeu, Guillermo Garcia-Manero, Rami S. Komrokji, Mikkael A. Sekeres, Matteo Giovanni Della Porta, Alan F List, Mario Cazzola, Amy E. DeZern, Gail J. Roboz, David P. Steensma, Arjan A van de Loosdrecht, Arjan A van de Loosdrecht, Richard F. Schlenk, Xavier Calvo, Sabine Blum, Arturo Pereira, Peter Valent, Dolors Costa, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, Carmen Pedro, Michael Lübbert, Maria Teresa Cedena, Sigrid Machherndl-Spandl, Maria Lopez-Pavia, Detlef Haase, Ana Africa Martin, Claudia D Baldus, Montserrat Martínez de Sola, Reinhard Stauder, Brayan Merchan, Claudia Mende, María Teresa Ardanaz, Christina Ganster, Francesc Cobo, Thomas Schroeder, Jordi Esteve, Rainer Haas, Nomdedeu Benet, Peter L. Greenberg, Ulrich Germing, Guillermo Sanz
Journal: Blood (2015)
Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach
Authors: Nikolaos Koutsouleris, René S Kahn, Adam M Chekroud, Stefan Leucht, Peter Falkai, Thomas Wobrock, Eske M Derks, Wolfgang W Fleischhacker, Alkomiet Hasan
Journal: The Lancet Psychiatry (2016)
Chronic Granulomatous Disease In Patients Reaching Adulthood: A Nationwide Retrospective Study Of 80 Cases In France
Authors: Bertrand Dunogué, Benoit Pilmis, Nizar Mahlaoui, Caroline Elie, Hélène Coignard-Biehler, Karima Amazzough, Nicolas Noël, Hélène Salvator, Fanny Fouyssac, Dominique Plantaz, Maire-Anne Gougerot-Pocidalo, Vincent Barlogis, Agathe Masseau, Isabelle Durieu, Marc Lecuit, Felipe Suarez, Alain Fischer, Stéphane Blanche, Olivier Lortholary, Olivier Hermine
Journal: Blood (2013)
Chromatin-Remodeling Complex SWI/SNF Controls Multidrug Resistance by Transcriptionally Regulating the Drug Efflux Pump ABCB1
Authors: Ramin Dubey, Andres M. Lebensohn, Zahra Bahrami-Nejad, Caleb Marceau, Magali Champion, Olivier Gevaert, Branimir I. Sikic, Jan E. Carette, Rajat Rohatgi
Journal: Cancer Research (2016)

Anthracyclines are among the most effective yet most toxic drugs used in the oncology clinic. The nucleosome-remodeling SWI/SNF complex, a potent tumor suppressor, is thought to promote sensitivity to anthracyclines by recruiting topoisomerase IIa (TOP2A) to DNA and increasing double-strand breaks. In this study, we discovered a novel mechanism through which SWI/SNF influences resistance to the widely used anthracycline doxorubicin based on the use of a forward genetic screen in haploid human cells, followed by a rigorous single and double-mutant epistasis analysis using CRISPR/Cas9-mediated engineering. Doxorubicin resistance conferred by loss of the SMARCB1 subunit of the SWI/SNF complex was caused by transcriptional upregulation of a single gene, encoding the multidrug resistance pump ABCB1. Remarkably, both ABCB1 upregulation and doxorubicin resistance caused by SMARCB1 loss were dependent on the function of SMARCA4, a catalytic subunit of the SWI/SNF complex. We propose that residual SWI/SNF complexes lacking SMARCB1 are vital determinants of drug sensitivity, not just to TOP2A-targeted agents, but to the much broader range of cancer drugs effluxed by ABCB1. Cancer Res; 76(19); 5810-21. ©2016 AACR.
Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199
Authors: Sharoon Akhtar, Aneel Paulus, Kelara Samuel, Hassan Yousaf, Davitte Cogen, Vivek Roy, Taimur Sher, James M. Foran, Candido E. Rivera, Gerardo Colon-Otero, Sikander Ailawadhi, Asher Alban Chanan-Khan
Journal: Blood (2015)
Surgeon’s Responsibility for Patient Care—Reply
Authors: Michael Nurok, Nicholas Sadovnikoff, Bruce Gewertz
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Hemoglobin H-Constant Spring in North America: A Common Alpha Thalassemia with Frequent Complications.
Authors: Titi Singer, Hae-Young Kim, Nancy F Olivieri, Janet Kwiatkowski, Ashutosh Lal, Thomas D. Coates, Susan Carson, Melody J. Cunningham, Patricia J Giardina, Brigitta U Mueller, Charles Quinn, Elliott Vichinsky, Thalassemia Clinical Research Network
Journal: Blood (2008)
Proteolytic Cleavage of Endothelial Cell-Bound Von Willebrand Factor Polymers by ADAMTS13 in the Absence of Flow Shear Stress
Authors: Shengyu Jin, Christopher G. Skipwith, Dezhi Shang, Chandrasekaran Nagaswami, John W. Weisel, X. Long Zheng
Journal: Blood (2008)
The epigenome: the next substrate for engineering
Authors: Minhee Park, Albert J. Keung, Ahmad S. Khalil
Journal: Genome biology (2016)

We are entering an era of epigenome engineering. The precision manipulation of chromatin and epigenetic modifications provides new ways to interrogate their influence on genome and cell function and to harness these changes for applications. We review the design and state of epigenome editing tools, highlighting the unique regulatory properties afforded by these systems.
Rapidly Progressive Quadriplegia and Encephalopathy
Authors: DonRaphael Wynn, Donald McCorquodale, Angela Peters, Kelsey Juster-Switlyk, Gordon Smith, Safdar Ansari
Journal: JAMA Neurology (2016)

A woman aged 77 years was transferred to our neurocritical care unit for evaluation and treatment of rapidly progressive motor weakness and encephalopathy. Examination revealed an ability to follow simple commands only and abnormal movements, including myoclonus, tongue and orofacial dyskinesias, and opsoclonus. Imaging study findings were initially unremarkable, but when repeated, they demonstrated enhancement of the cauda equina nerve roots, trigeminal nerve, and pachymeninges. Cerebrospinal fluid examination revealed mildly elevated white blood cell count and protein levels. Serial electrodiagnostic testing demonstrated a rapidly progressive diffuse sensory motor axonopathy, and electroencephalogram findings progressed from generalized slowing to bilateral periodic lateralized epileptiform discharges. Critical details of her recent history prompted a diagnostic biopsy. Over time, the patient became completely unresponsive with no further abnormal movements and ultimately died. The differential diagnosis, pathological findings, and diagnosis are discussed with a brief review of a well-known yet rare diagnosis.
Interleukin-10 Gene Polymorphism Reflects the Severity of Chronic Idiopathic Thrombocytopenic Purpura.
Authors: Takayuki Saitoh, Tetsuhiro Kasamatsu, Madoka Inoue, W.H.S. Al-ma’Quol, Akihiko Yokohama, Hiroshi Handa, Takafumi Matsushima, Norifumi Tsukamoto, Masamitsu Karasawa, Hatsue Ogawara, Yoshihisa Nojima, Hirokazu Murakami
Journal: Blood (2007)
Impact of Gleason score 4+3 on biochemical treatment failure in Japanese patients treated with monotherapeutic permanent interstitial brachytherapy.
Authors: T. Uesugi, T. Saika, K. Edamura, F. Abarzua, Y. Nasu, H. Kumon, H. Yanai
Journal: Journal of Clinical Oncology (2010)

e15108 Background: The permanent prostate brachytherapy (PPB) with iodine-125 seeds has an indication in patients with organ-confined prostate cancer. Our objective is to reveal pretreatment factors which have impact on the biochemical freedom from failure (bFFF) in patients with permanent interstitial seed implants as monotherapy. Methods: Between January 2004 and July 2009, 414 consecutive prostate cancer patients with low or intermediate risk in criteria of NCCN guideline underwent PPB at single institution. All of the pre-treatment pathological diagnoses were made by a central pathologist. Biochemical recurrence was defined using the Phoenix definition. Multivariate analysis was performed for pathological/clinical features and bFFF. The Kaplan-Meier method was used to calculate rates of bFFF with the log rank test. Results: The median follow-up length was 36.0 months (range, 1.0-68.6 months). The 2 and 3-year bFFF rates were 98.3% and 96.0%, respectively, for the entire cohort. Pretreatment Gleason score (p<0.0001) had strong impact on bFFF while risk group (p=0.0534) and clinical stage (p=0.563) did not. Especially, patients with GS 4+3 showed lower bFFF than patients with GS 3+4 (p=0.0267 ). Conclusions: Although clinical risk classification has contributed to predict biochemical failure rate in patients with PPB, the patients with Gleason sum score 7 should be divided to group 3+4 and group 4+3 since the clinical outcome may be different between these groups. Therefore, an indication of PPB for patients with Gleason 4+3 may be controversial. No significant financial relationships to disclose.
Non-Intensive AML/MDS Treatment with Low-Dose Decitabine Prior to Reduced-Intensity Conditioning (RIC) and Allogeneic Blood Stem Cell Transplantation of Older Patients.
Authors: Michael Lübbert, Hartmut Bertz, Björn H. Rüter, Roland H. Mertelsmann, Jürgen Finke
Journal: Blood (2006)
The burden of proof for a cultural group selection account
Authors: Pat Barclay, Daniel Brian Krupp
Journal: Behavioral and Brain Sciences (2016)

Abstract Richerson et al. establish cultural group selection as a plausible force in human social evolution. However, they do not demonstrate its causal precedence for any trait, let alone its “essentialness.” To do so, they must show that a particular group trait was caused by cultural transmission, and directly caused differences in group fitness.
Efficacy and safety of everolimus for heavily pretreated patients with ER+/HER2- metastatic breast cancer.
Authors: Tomofumi Osako, Reiki Nishimura, Yasuyuki Nishiyama, Mamiko Fujisue, Mitsuhiro Yamada, Kyoko Suko, Junko Morioka
Journal: Journal of Clinical Oncology (2016)

e12041 Background: Everolimus is effective for patients with ER+/HER2- metastatic breast cancer. In BORELO 2 trial, about the half of the patients were treated previously with less than two therapies and the sensitivity to the previous endocrine therapy was more than 80%. However, efficacy and safety of everolimus for heavily pretreated patients with metastatic breast cancer are unknown. Methods: From April 2014 to January 2016, 35 patients with ER+/ HER2- metastatic breast cancer were treated with everolimus in our hospital. Most patients received more than 3 endocrine therapies after recurrence. We examined their clinical backgrounds and outcomes. Results: The median follow-up time was 11.1 months. Forty-eight percent of patients had metastases in one organ, 28% in 2 organs and 24% in more than 3 organs. Twenty-four percent of patients had lung metastasis, 38% had liver metastasis and 42% had bone metastasis. Eighty percent of patients received more than 3 endocrine therapies after recurrence. Responses for more than 6 months to the previous endocrine therapies were confirmed in 32% of patients. Fifty-five percent of patients were treated with chemotherapy after recurrence. Complete response was obtained in 0% patient, partial response in 10%, stable disease in 59% and progressive disease in 14%. The median progression-free survival with everolimus treatment was 114 days. Seventy-two percent of patients had stomatitis (G3 18%), 17% had pneumonitis (G3 3%) and 21% had dermatitis. The reasons of discontinuation of everolimus treatment were disease progression in 61% patients, pneumonitis in 17%, stomatitis in 17% and others in 4%. Thirty-four percent of patients continued treatment with 10mg/day of everolimus until progression. Three out of 4 patients who discontinued everolimus treatment because of stomatitis had taken 10mg/day of everolimus. All the 4 patients who discontinued everolimus treatment because of pneumonitis had taken 10mg/day of everolimus. Conclusions: There was no significant difference of response rates, however, the progression-free survival with everolimus treatment was shorter than that in BORELO 2 trial. We may control the severe adverse events by reducing the dose of everolimus.
Characteristics of infections associated with a spinal cord stimulator system
Authors: Erlangga Yusuf, Sven Bamps, Jean Paul Ursi, Elke Del Biondo, Kris De Smedt, Raf Van Paesschen, Dirk Berghmans, Tony Van Havenbergh, Jef Van Schaeren, Bruno Van Herendael
Journal: Journal of Infection (2016)
Increases in Fentanyl-Related Overdose Deaths — Florida and Ohio, 2013–2015
Authors: Alexis B. Peterson, R. Matthew Gladden, Chris Delcher, Erica Spies, Amanda Garcia-Williams, Yanning Wang, John Halpin, Jon Zibbell, Carolyn Lullo McCarty, Jolene DeFiore-Hyrmer, Mary DiOrio, Bruce A. Goldberger
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

In March and October 2015, the Drug Enforcement Administration (DEA) and CDC issued nationwide alerts identifying fentanyl, particularly illicitly manufactured fentanyl (IMF), as a threat to public health and safety (1,2). IMF is pharmacologically similar to pharmaceutical fentanyl (PF), but is unlawfully produced in clandestine laboratories, obtained via illicit drug markets, and includes fentanyl analogs. Fentanyl is a synthetic opioid 50-100 times more potent than morphine and approved for the management of surgical/postoperative pain, severe chronic pain, and breakthrough cancer pain.* DEA's National Forensic Laboratory Information System (NFLIS) collects drug identification results from drug cases analyzed by federal, state, and local forensic laboratories throughout the United States.(†) In 2014, 80% of fentanyl submissions (i.e., drug products obtained by law enforcement that tested positive for fentanyl) in NFLIS were identified from 10 states, including Florida and Ohio (2), and seven of these 10 states reported sharp increases in fentanyl-related overdose deaths (fentanyl deaths) (3). This report presents findings of increased fentanyl deaths during 2013-2015 from investigations conducted by the University of Florida and the Ohio Department of Public Health, in collaboration with CDC. Analyses examined the association between trends in fentanyl-related law enforcement submissions and fentanyl deaths and describes groups at risk for fentanyl death using medical examiner and coroner reports. The marked increases in fentanyl death in Florida and Ohio during 2013-2015 were closely associated with parallel increases in fentanyl submissions, with the largest impact on persons who use heroin, consistent with reports that IMF is commonly mixed with or sold as heroin (1,4). In Ohio, circumstances associated with fentanyl deaths included a current diagnosed mental health disorder(§) and recent release from an institution such as a jail, rehabilitation facility, or hospital.
Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections
Authors: E. Durante-Mangoni, R. Andini, S. Signoriello, G. Cavezza, P. Murino, S. Buono, M. De Cristofaro, C. Taglialatela, M. Bassetti, P. Malacarne, N. Petrosillo, A. Corcione, C. Viscoli, R. Utili, C. Gallo
Journal: Clinical Microbiology and Infection (2016)
Clinical Trial Registration and the ICMJE
Authors: Marc G H Besselink, Hein G Gooszen, Erik Buskens
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database
Authors: J.V. Brower, A. Amini, S. Chen, C.R. Hullett, R.J. Kimple, A.P. Wojcieszynski, M. Bassetti, M.E. Witek, M. Yu, P.M. Harari, A.M. Baschnagel
Journal: Annals of Oncology (2016)